Tags

Type your tag names separated by a space and hit enter

Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection.
Int J Antimicrob Agents. 2005 Nov; 26(5):357-65.IJ

Abstract

In this prospective, double-blind, multicentre trial, adult patients with complicated skin and skin structure infection (cSSSI) randomly received sequential intravenous (i.v.)/oral (p.o.) moxifloxacin (400 mg once a day) or a control regimen of i.v. piperacillin-tazobactam (3.0/0.375 g every 6 h) followed by p.o. amoxicillin-clavulanate (800 mg every 12 h), each for 7-14 days. Clinical cure rates at the test-of-cure visit (10-42 days post therapy) for the efficacy-valid population were 79% (143/180) for the moxifloxacin-treated group and 82% (153/187) for the control group (95% confidence interval, -12.04, 3.29). Bacteriological eradication rates for Staphylococcus aureus, the most prevalent organism, were 78% and 80%, respectively. The incidence of drug-related adverse events was similar for both groups (31% moxifloxacin, 30% control). Sequential i.v./p.o. moxifloxacin was as effective and well tolerated as i.v. piperacillin-tazobactam followed by p.o. amoxicillin-clavulanate in treating patients with cSSSI.

Authors+Show Affiliations

Orlando Regional Medical Center (ORMC), Orlando, FL, USA. pgiordano@cfl.rr.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16229991

Citation

Giordano, Philip, et al. "Sequential Intravenous/oral Moxifloxacin Versus Intravenous Piperacillin-tazobactam Followed By Oral Amoxicillin-clavulanate for the Treatment of Complicated Skin and Skin Structure Infection." International Journal of Antimicrobial Agents, vol. 26, no. 5, 2005, pp. 357-65.
Giordano P, Song J, Pertel P, et al. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents. 2005;26(5):357-65.
Giordano, P., Song, J., Pertel, P., Herrington, J., & Kowalsky, S. (2005). Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. International Journal of Antimicrobial Agents, 26(5), 357-65.
Giordano P, et al. Sequential Intravenous/oral Moxifloxacin Versus Intravenous Piperacillin-tazobactam Followed By Oral Amoxicillin-clavulanate for the Treatment of Complicated Skin and Skin Structure Infection. Int J Antimicrob Agents. 2005;26(5):357-65. PubMed PMID: 16229991.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. AU - Giordano,Philip, AU - Song,James, AU - Pertel,Peter, AU - Herrington,Janet, AU - Kowalsky,Steven, Y1 - 2005/10/17/ PY - 2005/04/27/received PY - 2005/07/27/accepted PY - 2005/10/19/pubmed PY - 2006/1/26/medline PY - 2005/10/19/entrez SP - 357 EP - 65 JF - International journal of antimicrobial agents JO - Int J Antimicrob Agents VL - 26 IS - 5 N2 - In this prospective, double-blind, multicentre trial, adult patients with complicated skin and skin structure infection (cSSSI) randomly received sequential intravenous (i.v.)/oral (p.o.) moxifloxacin (400 mg once a day) or a control regimen of i.v. piperacillin-tazobactam (3.0/0.375 g every 6 h) followed by p.o. amoxicillin-clavulanate (800 mg every 12 h), each for 7-14 days. Clinical cure rates at the test-of-cure visit (10-42 days post therapy) for the efficacy-valid population were 79% (143/180) for the moxifloxacin-treated group and 82% (153/187) for the control group (95% confidence interval, -12.04, 3.29). Bacteriological eradication rates for Staphylococcus aureus, the most prevalent organism, were 78% and 80%, respectively. The incidence of drug-related adverse events was similar for both groups (31% moxifloxacin, 30% control). Sequential i.v./p.o. moxifloxacin was as effective and well tolerated as i.v. piperacillin-tazobactam followed by p.o. amoxicillin-clavulanate in treating patients with cSSSI. SN - 0924-8579 UR - https://www.unboundmedicine.com/medline/citation/16229991/Sequential_intravenous/oral_moxifloxacin_versus_intravenous_piperacillin_tazobactam_followed_by_oral_amoxicillin_clavulanate_for_the_treatment_of_complicated_skin_and_skin_structure_infection_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-8579(05)00228-1 DB - PRIME DP - Unbound Medicine ER -